HRP20020881A2 - Method for the preparation of citalopram - Google Patents
Method for the preparation of citalopramInfo
- Publication number
- HRP20020881A2 HRP20020881A2 HRP20020881A HRP20020881A2 HR P20020881 A2 HRP20020881 A2 HR P20020881A2 HR P20020881 A HRP20020881 A HR P20020881A HR P20020881 A2 HRP20020881 A2 HR P20020881A2
- Authority
- HR
- Croatia
- Prior art keywords
- formula
- compound
- image
- prepared
- reaction
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 37
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 title claims description 25
- 229960001653 citalopram Drugs 0.000 title claims description 25
- 238000002360 preparation method Methods 0.000 title claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 60
- 238000006243 chemical reaction Methods 0.000 claims description 31
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 230000029936 alkylation Effects 0.000 claims description 17
- 238000005804 alkylation reaction Methods 0.000 claims description 17
- -1 benzyl halide Chemical class 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 239000003638 chemical reducing agent Substances 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 10
- 239000012024 dehydrating agents Substances 0.000 claims description 9
- 238000006798 ring closing metathesis reaction Methods 0.000 claims description 7
- 230000001430 anti-depressive effect Effects 0.000 claims description 6
- 239000000935 antidepressant agent Substances 0.000 claims description 5
- 229940005513 antidepressants Drugs 0.000 claims description 5
- 238000007098 aminolysis reaction Methods 0.000 claims description 4
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 claims description 4
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 2
- 150000002576 ketones Chemical class 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 45
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 19
- 239000012279 sodium borohydride Substances 0.000 description 18
- 229910000033 sodium borohydride Inorganic materials 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 239000000725 suspension Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 7
- 239000012280 lithium aluminium hydride Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- IGEKIFWYHHOBIB-UHFFFAOYSA-N 1-(4-fluorophenyl)-3-oxo-1h-2-benzofuran-5-carboxylic acid Chemical compound O1C(=O)C2=CC(C(=O)O)=CC=C2C1C1=CC=C(F)C=C1 IGEKIFWYHHOBIB-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 229910010084 LiAlH4 Inorganic materials 0.000 description 6
- 229910006124 SOCl2 Inorganic materials 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical group [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical group 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 230000002152 alkylating effect Effects 0.000 description 4
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 4
- 229910000091 aluminium hydride Inorganic materials 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- HHVIBTZHLRERCL-UHFFFAOYSA-N methylsulphonylmethane Natural products CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ADGFGICBGFREFM-UHFFFAOYSA-N 3-[5-(aminomethyl)-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]-n,n-dimethylpropan-1-amine Chemical compound O1CC2=CC(CN)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 ADGFGICBGFREFM-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- 238000003747 Grignard reaction Methods 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 3
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 3
- 239000012485 toluene extract Substances 0.000 description 3
- TVZPFXMISWZNCC-UHFFFAOYSA-N 1-(4-fluorophenyl)-3-oxo-1h-2-benzofuran-5-carboxamide Chemical compound O1C(=O)C2=CC(C(=O)N)=CC=C2C1C1=CC=C(F)C=C1 TVZPFXMISWZNCC-UHFFFAOYSA-N 0.000 description 2
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 2
- OWQCIMGISJMQQQ-UHFFFAOYSA-N 5-(bromomethyl)-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran Chemical compound C1=CC(F)=CC=C1C1C2=CC=C(CBr)C=C2CO1 OWQCIMGISJMQQQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229910002567 K2S2O8 Inorganic materials 0.000 description 2
- 229910017852 NH2NH2 Inorganic materials 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229910006121 SOBr2 Inorganic materials 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000019394 potassium persulphate Nutrition 0.000 description 2
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- QJKHENCJQIAEBH-UHFFFAOYSA-N (Methylsulfinyl)methanide Chemical compound CS([CH2-])=O QJKHENCJQIAEBH-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- YXCRMKYHFFMNPT-UHFFFAOYSA-N 1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound C1=CC(F)=CC=C1C1C2=CC=C(C#N)C=C2CO1 YXCRMKYHFFMNPT-UHFFFAOYSA-N 0.000 description 1
- VVXGNGGTQDOLGK-UHFFFAOYSA-N 1-(4-fluorophenyl)-3-oxo-1h-2-benzofuran-5-carbonitrile Chemical compound C1=CC(F)=CC=C1C1C2=CC=C(C#N)C=C2C(=O)O1 VVXGNGGTQDOLGK-UHFFFAOYSA-N 0.000 description 1
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
- ASGSMDPSNUXWMB-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3-oxo-2-benzofuran-5-carbonitrile Chemical compound O1C(=O)C2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 ASGSMDPSNUXWMB-UHFFFAOYSA-N 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- XEEGWTLAFIZLSF-UHFFFAOYSA-N 1-oxo-3h-2-benzofuran-5-carbonitrile Chemical compound N#CC1=CC=C2C(=O)OCC2=C1 XEEGWTLAFIZLSF-UHFFFAOYSA-N 0.000 description 1
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 1
- HCYFGRCYSCXKNQ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxo-7-purinyl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 HCYFGRCYSCXKNQ-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- DPZHKLJPVMYFCU-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)acetonitrile Chemical compound BrC1=CC=C(CC#N)N=C1 DPZHKLJPVMYFCU-UHFFFAOYSA-N 0.000 description 1
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NYYRRBOMNHUCLB-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCCl NYYRRBOMNHUCLB-UHFFFAOYSA-N 0.000 description 1
- JVUHTPARUDQETP-UHFFFAOYSA-N 4-(4-fluorobenzoyl)benzene-1,3-dicarboxylic acid Chemical compound OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)C1=CC=C(F)C=C1 JVUHTPARUDQETP-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- IUSPXLCLQIZFHL-UHFFFAOYSA-N 5-bromo-3h-2-benzofuran-1-one Chemical compound BrC1=CC=C2C(=O)OCC2=C1 IUSPXLCLQIZFHL-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ULHAYYQQMCXNET-UHFFFAOYSA-N [1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-yl]methanamine Chemical compound O1CC2=CC(CN)=CC=C2C1C1=CC=C(F)C=C1 ULHAYYQQMCXNET-UHFFFAOYSA-N 0.000 description 1
- POHDLHGSZNINFC-UHFFFAOYSA-N [1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-yl]methanol Chemical compound O1CC2=CC(CO)=CC=C2C1C1=CC=C(F)C=C1 POHDLHGSZNINFC-UHFFFAOYSA-N 0.000 description 1
- ALIGTYPNWJPIKT-UHFFFAOYSA-M [Cl-].FC1=CC=C([Mg+])C=C1 Chemical compound [Cl-].FC1=CC=C([Mg+])C=C1 ALIGTYPNWJPIKT-UHFFFAOYSA-M 0.000 description 1
- 229950003769 acefylline Drugs 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- NGPAITITALWALP-UHFFFAOYSA-M magnesium;n,n-dimethylpropan-1-amine;chloride Chemical compound [Mg+2].[Cl-].CN(C)CC[CH2-] NGPAITITALWALP-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- VGVQONUNFQAXBP-UHFFFAOYSA-N methyl 1-(4-fluorophenyl)-3-oxo-1h-2-benzofuran-5-carboxylate Chemical compound O1C(=O)C2=CC(C(=O)OC)=CC=C2C1C1=CC=C(F)C=C1 VGVQONUNFQAXBP-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- LGQLOGILCSXPEA-UHFFFAOYSA-L nickel sulfate Chemical compound [Ni+2].[O-]S([O-])(=O)=O LGQLOGILCSXPEA-UHFFFAOYSA-L 0.000 description 1
- 229910000363 nickel(II) sulfate Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical class C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- VFGUZPZNOAEVCT-UHFFFAOYSA-L potassium sodium hydrogen sulfate hydroxide Chemical compound S(=O)(=O)([O-])O.[K+].[OH-].[Na+] VFGUZPZNOAEVCT-UHFFFAOYSA-L 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
Description
Ovaj se izum odnosi na način priprave dobro poznatog antidepresiva citaloprama, 1-[3-(dimetilamino)propil]-1-(4-fluorofenil)-1,3-dihidro-5-izobenzofurankarbonitrila.
Prethodno stanje struke
Citalopram je dobro poznati antidepresiv koji se već nekoliko godina nalazi na tržištu i koji ima sljedeću strukturu:
[image]
To je selektivni, centralno djelujući inhibitor ponovne pohrane serotonina (5-hidroksitriptamin; 5-HT), koji u skladu s time ima antidepresivno djelovanje. Antidepresivno djelovanje ovog spoja opisano je u nekoliko publikacija, npr. J. Hyttel Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1982., 6, 277-295 i A. Gravem, Acta Psychiatr. Scand. 1987., 75, 478-486. Osim toga se pokazalo da taj spoj ima učinka u liječenju demencije i cerebrovaskularnih poremećaja, EP-A 474580.
Citalopram je prvi put opisanu DE 2,657,013, što odgovara US 4,136,193. Ta patentna objava opisuje pripravu citaloprama na jedan način i naznačuje daljnji način koji se može primijeniti za pripravu citaloprama.
Prema opisanom postupku, na odgovarajući 1-(4-fluorofenil)-1,3-dihidro-5-izobenzofurankarbonitril reagira se s 3-(N,N-dimetilamino)propil-kloridom uz prisutnost metilsulfinilmetilda kao kondenzirajućeg agensa. Polazna supstanca pripravljena je iz odgovarajućeg 5-bromo derivata reakcijom s bakrenim cijanidom.
Prema tom načinu, koji je samo naznačen u općim crtama, citalopram se može dobiti zatvaranjem prstena spoja
[image]
uz prisutnost dehidrirajućeg agensa te zatim zamjenom 5-bromo grupe s bakrenim cijanidom. Početna supstanca formule II dobivena je iz 5-bromoftalida pomoću dviju uzastopnih Grignardovih reakcija, tj. s 4-fluorofenil magnezijevim kloridom odnosno N,N-dimetilaminopropil magnezijevim kloridom.
Nov i neočekivan način i intermedier za pripravu citaloprama opisani su SAD patentu br. 4,650,884, prema kojemu se intermedier formule
[image]
podvrgava zatvaranju prstena dehidracijom pomoću jake sumporne kiseline kako bi se dobio citalopram. Intermedier formule III pripravljen je iz 5-cijanoftalida pomoću dviju uzastopnih Grignardovih reakcija, tj. s 4-fluorofenil magnezijevim halogenidom odnosno N,N-dimetilaminopropil magnezijevim halogenidom.
Daljnji postupci opisani su u Međunarodnim prijavama br. WO 98019511, WO 98019512 i WO 98019513. Prijave WO 98019512 i WO 98019513 odnose se na načine u kojima je 5-amino-, 5-karboksi- ili 5-(sek. aminokarbonil)ftalid podvrgnut dvjema uzastopnim Grignardovim reakcijama, zatvaranju prstena i konverziji dobivenog derivata 1,3-dihidroizobenzofurana u odgovarajući 5-cijano spoj, tj. citalopram. Međunarodna patentna prijava br. WO 98019511 opisuje postupak za dobivanje citaloprama u kojemu je spoj (4-supstituiranog-2-hidroksimetilfenil-(4-fluorofenil)metanola podvrgnut zatvaranju prstena, a dobiveni 5-supstituirani 1-(4-fluorofenil)-1,3-dihidroizobenzofuran konvertiran u odgovarajući 5-cijano derivat koji se alkilira s (3-dimetilamino)propilhalogenidom kako bi se dobio citalopram.
Konačno, načini priprave pojedinih enantiomera citaloprama opisani su u SAD patentu br. 4,943,590 iz kojeg je također vidljivo da se zatvaranje prstena intermediera formule III može provesti preko labilnog estera s bazom.
Sada se, iznenada, otkrilo da se citalopram može proizvoditi na nov, prikladan i siguran način uz uporabu odgovarajućih početnih supstanci.
Sažetak izuma
Dakle, ovaj se izum odnosi na nov način priprave citaloprama koji sadrži reakciju spoja formule IV
[image]
s prikladnim oksidirajućim agensom poput bakra(I) i O2; ili NiSO4 i K2S2O8 radi dobivanja citaloprama
[image]
koji se izolira kao baza njegove farmaceutski prihvatljive soli.
U drugom aspektu, ovaj se izum odnosi na načine priprave intermediera formule IV.
U još jednom aspektu, ovaj se izum odnosi na antidepresivnu farmaceutsku smjesu koja sadrži citalopram kao bazu ili bilo koju njegovu prikladnu sol dobivenu postupkom prema ovom izumu.
Osim toga prema ovom izumu, spojevi formule IV mogu se pripraviti na različite načine.
Jedan od tih načina sastoji se od sljedećih faza:
[image]
Na 6-karboksi-3-(4-fluorofenil)ftalid reagira se alkoholom, R-OH, gdje je R preferirano niži alkil, najradije Me, uz prisutnost dehidrirajućeg agensa, preferirano SOCl2.
Dobiveni spoj formule VI alkilira se s
[image]
gdje X predstavlja ostatak uz prisutnost odgovarajuće baze. X je preferirano halogen ili sulfonat.
Opcionalno, alkilirajuća reakcija je postepena alkilacija. U tom slučaju dobiveni spoj formule VI alkilira se sa spojem koji ima formulu
[image]
gdje je X' prikladan ostatak, a R' je -CH2-O-Pg, -CH2-NPg1Pg2, -CO-N(CH3)2, -CH(OR1)(OR2), -C(OR4)(OR5)(OR6) ili -COOR3, pri čemu je Pg zaštitna grupa za alkoholnu grupu, Pg1 i Pg2 su zaštitne grupe za amino grupu, R1 i R2 su alkilne grupe ili
R1 i R2 zajedno tvore lanac od 2 do 4 atoma ugljika, a R3, R4, R5 i R6 su alkil, alkenil, alkinil, aril ili aralkil;
kako bi nastao spoj formule XVIII
[image]
gdje je R' prema gornjoj definiciji; nakon čega slijedi konverzija grupe R' u dimetilaminometilnu grupu.
Na dobiveni spoj formule VII reagira se s reducirajućim agensom poput LiAlH4, Red-Al, AlH3 ili aktivnim oblicima NaBH4, npr. NaBH4, Me2SO4; NaBH4, I2; NaBH4, BF3. Et2O; ili B2H6; nakon čega slijedi tretiranje kiselinom ili nekim drugim dehidrirajućim agensom u svrhu zatvaranja prstena radi stvaranja spoja formule VIII.
Alkohol formule VIII prikladno se aktivira tosilkloridom ili mesikloridom kako bi nastao odgovarajući supstituirani sulfonat; ili se alkohol konvertira u odgovarajući benzilni halid. Ta se konverzija preferirano provodi sa SOBr2 ili COCl2.
Odgovarajući sulfonat ili halid konvertira se izravno u spoj formule IV pomoću reakcije s tekućim amonijakom
ili pomoću reakcije s metalnom soli ftalimida, preferirano kalijevog ftalimida, nakon čega slijedi tretiranje s NH2NH2 ili tretiranje aminom u alkoholu, tj. R8NH2/R9-OH, pri čemu su R8 i R9 niži alkil, preferirano metil ili etil, npr. metilamin u etanolu;
ili pomoću reakcije s metalnim azidom, MN3, s time da je M preferirano Na ili K; nakon čega slijedi tretiranje reducirajućim agensom poput Pd/C i H2 ili izvora hidrata poput LiAlH4 ili NaBH4 ili njegov aktivni oblik.
Drugi način za pripravu spoja formule IV sastoji se od sljedećih faza:
[image]
Na 6-karboksi-3-(4-fluorofenil)ftalid prikladno se reagira s dehidrirajućim agensom poput tionilklorida, a nakon toga slijedi aminoliza dobivenog aktiviranog kiselog derivata.
Dobiveni spoj formule IX alkilira se s
[image]
pri čemu je X ostatak uz prisutnost prikladne baze. X je preferirano halogen ili sulfonat.
Opcionalno, alkilirajuća reakcija je postepena alkilacija analogna gore opisanoj postepenoj alkilaciji.
Na dobiveni spoj formule X reagira se reducirajućim agensom poput LiAlH4, Red-Al, AlH3 ili aktivnim oblicima NaBH4, npr. NaBH4, Me2SO4; NaBH4, I2; NaBH4, BF3.Et2O; ili B2H6; nakon čega slijedi tretiranje kiselinom ili nekim drugim dehidrirajućim agensom u svrhu zatvaranja prstena radi stvaranja spoja formule IV.
Prema trećem načinu za pripravu spoja formule IV, pripravlja se odgovarajući 6-cijano supstituirani derivat 6-karboksi-3-(4-fluorofenil)ftalida.
[image]
Na karboksi derivat reagira se sa SOCl2, nakon čega slijedi tretiranje amonijakom i konačno dehidrirajući agens poput SOCl2 radi priprave cijano derivata formule XI;
ili se reagira alkoholom R-OH uz prisutnost kiseline, nakon čega slijedi tretiranje amonijakom i konačna reakcija sa SOCl2; ili se na njega postupkom u istoj posudi reagira sa SO2(NH2)2, SOCl2 i sulfolanom ili tert-butilaminom, dehidrirajućim agensom poput POCl3 i odgovarajućim otapalom poput toluena.
Dobiveni spoj formule XI alkilira se s
[image]
pri čemu je X ostatak uz prisutnost odgovarajuće baze. X je preferirano halogen ili sulfonat.
Opcionalno, alkilirajuća reakcija je postepena alkilacija analogna gore opisanoj postepenoj alkilaciji.
Na dobiveni spoj formule XII reagira se reducirajućim agensom poput LiAlH4, Red-Al, AlH3 ili aktivnim oblicima NaBH4, npr. NaBH4, Me2SO4; NaBH4, I2; NaBH4, BF3.Et2O; ili B2H6; nakon čega slijedi tretiranje kiselinom u svrhu zatvaranja prstena radi stvaranja spoja formule IV.
Drugi uvjeti reakcije, otapala itd. za gore opisane reakcije predstavljaju uobičajene uvjete za takve reakcije i stručnjak ih može lako odrediti.
U drugom aspektu, ovaj izum predstavlja novi intermedier formule V.
U još jednom aspektu, ovaj se izum odnosi na načine priprave intermediera formule V.
Jedan postepeni postupak priprave intermediera formule V prikazan je u nastavku:
[image]
Na m-ksilen i p-fluorobenzoil klorid, koji su komercijalno raspoloživi spojevi, reagira se uz prisutnost AlCl3, kako bi se dobio spoj formule XIV. Taj se spoj oksidira permanganatom, preferirano KMnO4 ili NaMnO4, što daje dobiveni spoj formule XIII, na koji se konačno prikladno reagira sa Zn u kiselini, preferirano octenoj kiselini.
Alternativno, spoj formule IV pripravlja se iz spoja formule XIII sljedećim postepenim postupkom:
[image]
Na spoj formule XIII reagira se reducirajućim agensom poput LiAlH4, Red-Al, AlH3 ili aktivnim oblicima NaBH4, npr. NaBH4, Me2SO4; NaBH4, I2; NaBH4, BF3.Et2O; ili B2H6; nakon čega slijedi tretiranje kiselinom u svrhu zatvaranja prstena radi stvaranja spoja formule XV.
Alkohol formule XV prikladno se aktivira tosilkloridom ili mesilkloridom radi stvaranja odgovarajućeg supstituiranog sulfonata; ili se alkohol konvertira u odgovarajući benzilski halid. Ta se konverzija preferirano provodi sa SOBr2 ili SOCl2.
Odgovarajući sulfonat ili halid konvertira se u spoj formule XVII izravno reakcijom s tekućim amonijakom;
ili reakcijom s metalnom soli ftalimida, preferirano kalijevog ftalimida, nakon čega slijedi tretiranje s NH2NH2 ili tretiranjem aminom u alkoholu, tj. R8NH2/R9-OH, pri čemu su R8 i R9 niži alkil, preferirano metil ili etil, npr. metilamin u etanolu;
ili reakcijom s metalnim azidom MN3, s time da je M preferirano Na ili K; nakon čega slijedi tretiranje reducirajućim agensom poput Pd/C i H2 ili izvora hidrida poput LiAlH4 ili NaBH4 ili njihovog aktivnog oblika.
Dobiveni spoj formule XVII alkilira se s
[image]
gdje je X ostatak uz prisutnost odgovarajuće baze. X je preferirano halogen ili sulfonat.
Opcionalno, alkilirajuća reakcija je postepena alkilacija analogna gore opisanoj postepenoj alkilaciji.
Opcionalno su faze alkilacije i konverzija u cijano derivat u suprotnom poretku, pa se konverzija u cijano derivat obavlja prije alkilacije.
U svim specifikacijama i patentnim zahtjevima, izraz niži alkil ili C1-6 alkil odnosi se na razgranatu ili nerazgranatu alkilnu grupu koja ima jedan do uključivo šest ugljikovih atoma, poput metila, etila, 1-propila, 2-propila, 1-butila, 2-butila, 2-metil-2-propila, 2,2,-dimetil-1-etila i 2-metil-1-propila.
Slično tome, alkil odnosno alkinil označavaju takve grupe sa dva do šest atoma ugljika, uključujući jednu dvostruku odnosno trostruku vezu, poput etenila, propenila, butenila, etinila, propinila i butinila.
Izraz aril odnosi se na mono- ili bicikličku karbocikličku aromatsku grupu, poput fenila i naftila, posebno fenila.
Izraz aralkil odnosi se na aril-alkil, pri čemu su aril i alkil prema gornjoj definiciji.
Halogen znači klor, brom ili jod.
Spoj opće formule I može se koristiti kao slobodna baza ili njezina farmaceutaki prihvatljiva kiselinska sol. Kao kiselinske soli mogu se rabiti soli nastale iz organskih ili anorganskih kiselina. Primjeri takvih organskih soli su one s maleinskom, fumarnom, benzojevom, askorbinskom, jantarnom, oksalnom, bimetilensalicilnom, metansulfonskom, etandisulfonskom, octenom, propionskom, vinskom, salicilnom, limunskom, glukonskom, mliječnom, jabučnom, bademovom, cinamičnom, citrakonskom, asparaginskom, stearinskom, palmitinskom, itakonskom, glikolnom, p-aminobenzojevom, glutaminskom, benzensulfonskom i teofilinskom octenom kiselinom, kao i 8-haloteofilini, na primjer 8-bromoteofilin. Primjeri takvih anorganskih soli su one sa solnom, hidrobromnom, sumpornom, sulfaminskom, fosfornom i dušičnom kiselinom.
Kiselinske soli spojeva mogu se pripravljati na načine poznate u struci. Na bazu se reagira bilo s izračunatom količinom kiseline u otapalu koje se miješa s vodom, poput acetona ili etanola, pri čemu se nakon toga sol izolira koncentracijom i hlađenjem, bilo sa suviškom kiseline u otapalu koje se ne miješa s vodom, poput etiletera, etilacetata ili diklorometana, pri čemu se sol separira sama od sebe.
Farmaceutske smjese prema ovom izumu mogu se primjenjivati na bilo koji prikladan način i u bilo kojem prikladnom obliku, na primjer oralno u obliku tableta, kapsula, prašaka ili sirupa ili parenteralno u obliku uobičajenih sterilnih otopina za ubrizgavanje.
Farmaceutske formulacije prema ovom izumu mogu se pripraviti na načine uobičajene u struci. Na primjer, tablete se mogu pripraviti miješanjem aktivne tvari s običnim pomoćnim tvarima i/ili razrjeđivačima te zatim komprimiranjem mješavine u konvencionalnom stroju za tabletiranje. Primjeri pomoćnih tvari ili razrjeđivača su: škrobno brašno, krumpirovo škrobno brašno, talk, magnezijev stearat, želatina, laktoza, vezivna sredstva i slično. Može se rabiti bilo koja druga pomoćna tvar ili aditiv, boja, aroma, konzervans itd. pod uvjetom da su kompatibilni s aktivnom tvari.
Otopine za ubrizgavanje mogu se pripraviti otapanjem aktivnih tvari i eventualnih aditiva u dijelu otapala za ubrizgavanje, preferirano sterilnoj vodi, uz podešavanje otopine na željeni volumen, sterilizaciju otopine i njezino punjenje u prikladne ampule ili bočice. Mogu se dodati bilo kakvi prikladni aditivi koje rabi struka, poput tonizirajućih agensa, konzervansa, antioksidansa itd.
Primjeri
Ovaj izum u nastavku ilustriraju sljedeći primjeri.
Primjer 1
5-Aminometil-1-(3-dimetilamino-propil)-1-(4-fluorofenil)-1,3-dihidroizobenzofuran
1-(3-Dimetilamino-propil)-1-(4-fluorofenil)-3-okso-1,3-dihidroizobenzofuran-5-karbonitril (5,4 g, 16,2 mmol) otopljen je u suhom THF (5 mL) i razrijeđen suhim eterom (50 mL). Ta je otopina kap po kap dodavana suspenziji u refluksu litijevog aluminijevig hidrida (2,5 g, 65 mmol) u suhom eteru (150 mL) tijekom 10 - 15 minuta, nakon čega je dobivena suspenzija zagrijana do temperature refluksa i refluksirana daljnja 4 sata. Otopina je zatim ostavljena da se ohladi na sobnu temperaturu i preko noći miješana na sobnoj temperaturi. Reakcija je ugašena minimumom vode, a dobivena otopina/suspenzija osušena je na bezvodnom magnezijevom sulfatu. Ta je mješavina profiltrirana, a krutina je isprana s THF. Kombinirani filtrati upareni su radi dobivanja ulja. Ulje je otopljeno u toluenu (200mL) i 3 sata miješano s vodenom otopinom sumporne kiseline (10 ml, 70% v/v). Mješavina je otopljena u vodi, a pH je dodavanjem vodene otopine amonijaka (25% w/v) podešen na >9. Toluen je separiran, a vodena faza je ekstrahirana s daljnjom količoinom toluena. Kombinirani ekstrakti toluena osušeni su na bezvodnom magnezijevom sulfatu, filtrirani i upareni, kako bi se dobio naslovni spoj u obliku žutog ulja (4,4 g, 84%). 1H NMR (CDCl3): δ 1,25-1,40 (m, 1H); 1,40-1,55 (m, 1H); 2, 11 (ddd, 1H); 2,13 (t, 3 H); 2,15 (ddd, 1H); 2,21 (t, 2H); 3,85 (s, 2H); 5,11 (d, 1H); 5,14 (d, 1H); 6,96 (t,2H); 7,15 (s, 1H); 7,21 (d, 1H); 7,22 (d, 1H); 7,45 (dd, 2H).
Primjer 2
Citalopram, HBr
Mješavina 5-aminometil-1-(3-dimetilamino-propil)-1-(4-fluorofenil)-1,3-dihidroizobenzofu-rana (10g, 30 mmol) i 5 Ǻ molekularnih sita (24 g) u piridinu (150 mL) miješana je na 60°C u atmosferi kisika. Dodan je bakreni(I) klorid (1,8 g, 1,8 mmol), a mješavina je miješana 3 sata. Dodano je još bakrenog(I) klorida (1,8 g, 1,8 mmol) i ta je mješavina miješana preko noći. Zatim je mješavina prelivena na led, a pH mješavine je dodavanjem vodene otopine amonijaka (25% w/v) podešen na >9. Otopina je razrijeđena toluenom i profiltrirana. Organska faza je separirana, a vodena isprana daljnjom količinom toluena. Kombinirani organski ekstrakti isprani su vodom, osušeni na bezvodnom natrijevom sulfatu i upareni. Talog je tretiran heptanom i uparen radi dobivanja ulja (11,1 g). To je ulje otopljeno u acetonu i tretirano vodenom otopinom hidrobromne kiseline (7 ml, 47% w/v). Ta je otopina uparena, a talog je otopljen u izo-propanolu (100 mL). Otopina je miješana preko noći. Dobiveni je talog profiltriran i osušen kako bi se dobila HBr sol citaloprama u obliku bijelog praha (8,2 g, 66%). Filtrat je uparen, a uljasti talog protresen s eterom i ostavljen preko noći. Filtriranje te otopine dalo je daljnju HBr sol citaloprama u obliku smeđe krutine (1,7 g, 14%). 1H NMR (d6-DMSO): δ 1,35-1,50 (m, 1H); 1,50-1,60 (m, 1H); 2,25 (t, 2H); 2,69 (2, 3H); 3,00-3,10 (m, 2H); 5,17 (d, 1H); 5,25 (d, 1H); 7,18 (7, 2H); 7,61 (dd, 2H); 7,77 (6, 1H); 7,82 (d, 1H); 7,83 (s, 1H); 9,27 (bs, 1H).
Primjer 3
1-(4-Fluorofenil)-3-okso-1,3-dihidroizobenzofuran-5-karboksiln kiseli metil ester
Miješana suspenzija 1-(4-fluorofenil)-3-okso-1,3-dihidroizobenzofuran-5-karboksilne kiseline (1 g, 3,7 mmol) u tionil kloridu (25 mL) zagrijana je do refluksa i refluksirana 25 min, tijekom kojeg vremena se krutina otopila. Zatim je tionil klorid uparen, a ostatak otopljen u toluenu i ponovno uparen. Ostatak je preko noći miješan u etanolu (25 mL), tijekom čega je nastao debeli talog. Otapalo je upareno, a ostatak je podijeljen na vodenu otopinu amonijaka (25% w/v) i toluena. Organska faza je separirana, osušena na magnezijevom sulfatu i uparena radi dobivanja naslovnog spoja u obliku bijele krutine (0,97 g, 92%). 1H NMR (d6-DMSO): δ 3,92 (s, 3H); 6,85 (s, 1H); 7,26 (t, 2H); 7,42 (dd, 2H); 7,61 (d, 1H); 8,31 (dd, 1H); 8,36 (s, 1H).
Primjer 4
1-(4-Fluorofenil)-3-okso-1,3-dihidroizobenzofuran-5-karboksilni kiseli amid
Miješana suspenzija 1-(4-fluorofenil)-3-okso-1,3-dihidroizobenzofuran-5-karbolne kiseline (1 g, 3,7 mmol) u tionil kloridu (25 mL) zagrijana je do temperature refluksa i refluksirana 25 min, tijekom kojeg vremena se krutina otopila. Tionil klorid je zatim uparen, a ostatak otopljen u toluenu te ponovno uparen. Ostatak je otopljen u toluenu (15 mL) i tretiran otopinom amonijaka u eteru, te je nastao debeli talog. Mješavina je miješana preko noći, razrijeđena toluenom i vodenom otopinom amonijaka, te profiltrirana. Talog je osušen kako bi se dobio naslovni spoj u obliku bijele krutine (0,80 g, 80%). 1H MNR (d6-DMSO): δ 6,81 (s, 1H); 7,25 (t, 2H); 7,40 (dd, 2H); 7,54 (d, 1H); 7,59 (bs, 1H); 8,24 (bs, 1H); 8,24 (dd, 1H); 8,42 (s, 1H).
Primjer 5
1-(4-Fluorofenil)-3-okso-1,3-dihidroizobenzofuran-5-karbonitril
Suspenzija 1-(4-fluorfenil)-3-okso-1,3-dihidroizobenzofuran-5-karboksilnog kiselog amida (13,6 g, 0,05 mol) u tionil kloridu (40 mL) i DMF (0,25 mL) zagrijana je na temperaturu refluksa i refluksirana 2 sata. Zatim je tionil klorid uparen, a ostatak je otopljen u vrućem IPA (100 mL). Tijekom hlađenja nastali su kristali naslovnog spoja. Iskorištenje: 7,8 g (62%). 1H NMR (d6-DMSO): δ 6,87 (s, 1H); 7,26 (t, 2H); 7,42 (dd, 2H); 7,58 (d, 1H); 8.18 (dd, 1H); 8,48 (s, 1H).
Primjer 6
5-Bromometil-1-(4-fluorofenil)-1,3-dihidroizobenzofuran
Suspenzija 5-hidroksimetil-1-(4-fluorofenil)-1.3-dihidroizobenzofurana (2 g, 8,2 mmol) u toluenu (10 mL) grijana je sve dok se krutina nije otopila. Zatim je zagrijavanje zaustavljeno. Dodan je tionil bromid (2,2 g, 10,6 mmol) i ta je mješavina miješana 1 sat. Dodana je silicija (25 g), nakon čega je mješavina profiltrirana, a ostatak ispran s 1:1 v/v otopinom etil acetata i heptana. Filtrat je uparen kako bi se dobio naslovni spoj u obliku crveno-narančastog ulja (2,6 g, 90%). 1H NMR (d6-DMSO): δ 4,72 (s, 1H); 5,11 (d, 1H); 5,28 (d, 1H); 6,17 (s, 1H); 7,04 (d, 1H); 7,17 (t, 2H); 7,33 (d, 1H); 7,38 (dd, 2H); 7,45 (s, 1H).
Primjer 7
5-Aminometil-1-(4-fluorofenil)-1,3-dihidroizobenzofuran
Suspenzija 5-bromometil-1-(4-fluorofenil)-1,3-dihidroizobenzofurana (1,96 g, 6,4 mmol)
2 1⁄2 dana je miješana u tekućem redestiliranom amonijaku (200 mL) u atmosferi dušika/amonijaka na -33°C. Amonijak je ostavljen da se upari, a ostatak je miješan s mješavinom etil acetata i vodene otopine sumporne kiseline (2 M). Vodena faza je separirana i isprana eterom. Zatim je vodena faza pomoću vodene otopine amonijevog hidroksida (25% w/v) zalužena na pH >9 i ekstrahirana s toluenom. Ekstrakti toluena osušeni su na bezvodnom magnezijevom sulfatu i upareni kako bi se dobio naslovni spoj u obliku žuto-narančastog ulja (0,63 g, 40%). 1H NMR (d6-DMSO): δ 3,71 (s, 2H); 5,09 (d, 1H); 5,25 (dd, 1H); 6,14 (s, 1H); 6,96 (d, 1H); 7,17 (t, 2H); 7,20 (d, 1H); 7,32 (s, 1H); 7,36 (dd, 2H).
Primjer 8
Citalopram
Tijekom miješanja otopine 5-aminometil-1-(3-dimetilaminopropil)-1-(4-fluorofenil)-1,3-dihidroizobenzofurana (0,5 g, 1,5 mmol) u diklorometanu (10 mL) u nju je dodana vodena otopina kalijevog bisulfata i natrijevog hidroksida (19 mL; 0,2 M u K2S2O8, 3,8 mmol; 0,4 M u NaOH, 7,6 mmol), a zatim vodena otopina nikaljnog sulfata (1,5 mL, 40 mM, 61 μmol). Ta je mješavina snažno miješana 4 dana, a potom profiltrirana kroz celit. Filtrat je podijeljen na vodenu otopinu sumporne kiseline (2M) i toluen. Vodeni sloj je separiran, a dodavanjem vodene otopine amonijaka (25% w/v) pH mješavine podešen je na >9. Otopina je ekstrahirana toluenom, a potonji ekstrakt toluena osušen je na magnezijevom sulfatu i uparen radi dobivanja slobodne baze citaloprama u obliku vrlo blijedožutog ulja (0,35 g, 70%).
Primjer 9
1-(4-Fluorofenil)-3-okso-1,3-dihidroizobenzofuran-5-karboksilna kiselina
Napravljena je suspenzija cinka (38 g, 0,58 mol) u octenoj kiselini (400 mL). Mješavina je zagrijana na 60°C. U porcijama od po 5 grama dodan je 2,4-dikarboksi-4'-fluoro-benzofenon (21 g, 0,075 mol). Nakon tog dodavanja reakcijska mješavina je zagrijana na temperaturu refluksa i refluksirana 2 sata. Suspenzija je filtrirana dok je još bila vruća. Filtrat je dodan ledenoj vodi (1 kg) i filtriranjem je izoliran naslovni spoj. Iskorištenje 17,8 g (90%). 1H NMR (d6-DMSO): δ 6,84 (s, 1H); 7,17 (t, 2H); 7,43 (dd, 2H); 7,59 (d, 1H); 8,31 (d, 1H); 8,35 (s, 1H).
Claims (19)
1. Način priprave citaloprama naznačen time da sadrži reakciju spoja formule IV
[image]
s oksidirajućim agensom radi dobivanja citaloprama
[image]
koji se izolira kao baza ili njezina farmaceutski prihvatljiva sol.
2. Način prema patentnom zahtjevu 1, naznačen time da se intermedier formule IV pripravlja aktiviranjem alkohola formule VIII
[image]
pomoću supstituiranog sulfonata ili konverzijom alkohola u benzilski halid ili neki drugi aktivni derivat, nakon čega slijedi aminoliza radi stvaranja spoja formule IV
[image]
3. Način prema patentnom zahtjevu 2, naznačen time da se intermedier formule IV pripravlja pomoću reakcije spoja formule VII
[image]
s reducirajućim agensom.
4. Način prema patentnom zahtjevu 3, naznačen time da se intermedier formule VII pripravlja alkilacijom spoja formule VI
[image]
opcionalno postepenom alkilacijom.
5. Način prema patentnom zahtjevu 4, naznačen time da se intermedier formule VI pripravlja pomoću reakcije spoja formule V
[image]
s alkoholom R-OH uz prisutnost dehidrirajućeg agensa.
6. Način prema patentnom zahtjevu 1, naznačen time da se intermedier formule IV pripravlja pomoću reakcije spoja formule X
[image]
s reducirajućim agensom nakon čega slijedi zatvaranje prstena radi stvaranja spoja formule IV
[image]
7. Način prema patentnom zahtjevu 6, naznačen time da se intermedier formule X pripravlja alkilacijom spoja formule IX
[image]
opcionalno postepenom alkilacijom.
8. Način prema patentnom zahtjevu 1, naznačen time da se intermedier formule IX pripravlja pomoću reakcije spoja formule V
[image]
s dehidrirajućim agensom poput tionilklorida, nakon čega slijedi aminoliza dobivenog aktivnog derivata kiseline;
9. Način prema patentnom zahtjevu 1, naznačen time da se intermedier formule IV pripravlja pomoću reakcije spoja formule XII
[image]
s reducirajućim agensom, nakon čega slijedi zatvaranje prstena radi stvaranja spoja formule IV
[image]
10. Način prema patentnom zahtjevu 9, naznačen time da se intermedier formule XII pripravlja alkilacijom spoja formule XI
[image]
opcionalno postepenom alkilacijom.
11. Način prema patentnom zahtjevu 10, naznačen time da se intermedier formule XI pripravlja konverzijom spoja formule V
[image]
u odgovarajući cijano supstituirani spoj.
12. Spoj naznačen time da ima formulu V
[image]
13. Način priprave intermediera prema patentnom zahtjevu 12, naznačen time da sadržava reakciju zatvaranja prstena spoja formule XIII
[image]
s prikladnim reducirajućim agensom.
14. Način prema patentnom zahtjevu 13, naznačen time da je reducirajući agens Zn u kiselini, preferirano octenoj kiselini.
15. Način prema patentnom zahtjevu 1, naznačen time da se intermedier formule IV pripravlja alkilacijom spoja formule XVII
[image]
opcionalno postepenom alkilacijom radi stvaranja spoja formule IV
[image]
16. Način prema patentnom zahtjevu 15, naznačen time da se intermedier formule XVII pripravlja aminolizom spoja formule XVI
[image]
17. Način prema patentnom zahtjevu 16, naznačen time da se intermedier formule XVI pripravlja aktiviranjem alkohola formule XV
[image]
pomoću supstituiranog sulfonata ili konverzijom alkohola u benzilski halid ili neki drugi aktivni derivat.
18. Način prema patentnom zahtjevu 17, naznačen time da se intermedier formule XV pripravlja pomoću reakcije ketona formule XIII
[image]
s reducirajućim agensom, nakon čega slijedi zatvaranje prstena radi stvaranja spoja formule XV.
19. Antidepresivna farmaceutska smjesa naznačena time da sadrži citalopram proizveden postupkom prema bilo kojem od patentnih zahtjeva 1 - 11 i 13 - 18.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200000783 | 2000-05-12 | ||
PCT/DK2001/000333 WO2001085712A1 (en) | 2000-05-12 | 2001-05-10 | Method for the preparation of citalopram |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20020881A2 true HRP20020881A2 (en) | 2004-12-31 |
Family
ID=8159493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20020881 HRP20020881A2 (en) | 2000-05-12 | 2002-11-08 | Method for the preparation of citalopram |
Country Status (30)
Country | Link |
---|---|
US (1) | US6660873B2 (hr) |
EP (1) | EP1296970B1 (hr) |
JP (1) | JP2003532721A (hr) |
CN (1) | CN100422166C (hr) |
AR (1) | AR032455A1 (hr) |
AT (1) | ATE389645T1 (hr) |
AU (2) | AU5823901A (hr) |
BG (1) | BG65820B1 (hr) |
BR (1) | BR0110996A (hr) |
CA (1) | CA2408292C (hr) |
CZ (1) | CZ20024065A3 (hr) |
DE (1) | DE60133280T2 (hr) |
DK (1) | DK1296970T3 (hr) |
EA (1) | EA005674B1 (hr) |
ES (1) | ES2301541T3 (hr) |
HK (1) | HK1056171A1 (hr) |
HR (1) | HRP20020881A2 (hr) |
HU (1) | HUP0301942A2 (hr) |
IL (2) | IL152645A0 (hr) |
IS (1) | IS2586B (hr) |
MX (1) | MXPA02011125A (hr) |
NO (1) | NO327963B1 (hr) |
NZ (1) | NZ522475A (hr) |
PL (1) | PL358144A1 (hr) |
PT (1) | PT1296970E (hr) |
SI (1) | SI1296970T1 (hr) |
SK (1) | SK287035B6 (hr) |
UA (1) | UA72039C2 (hr) |
WO (1) | WO2001085712A1 (hr) |
ZA (1) | ZA200208973B (hr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2195554T5 (es) | 1999-04-14 | 2010-02-02 | H. Lundbeck A/S | Metodo para la preparacion de citalopram. |
US6310222B1 (en) * | 1999-11-01 | 2001-10-30 | Sumika Fine Chemicals Co., Ltd. | Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate |
US6433196B1 (en) | 2000-02-17 | 2002-08-13 | Sumika Fine Chemicals Co., Ltd. | Production method of citalopram, intermediate therefor and production method of the intermediate |
NL1017417C1 (nl) | 2000-03-03 | 2001-03-16 | Lundbeck & Co As H | Werkwijze voor de bereiding van Citalopram. |
JP2003527385A (ja) | 2000-03-13 | 2003-09-16 | ハー・ルンドベック・アクチエゼルスカベット | 5−置換された1−(4−フルオロフェニル)−1,3−ジヒドロイソベンゾフランの段階的アルキル化法 |
NL1017500C1 (nl) | 2000-03-13 | 2001-04-26 | Lundbeck & Co As H | Werkwijze voor de bereiding van Citalopram. |
AR032455A1 (es) | 2000-05-12 | 2003-11-12 | Lundbeck & Co As H | Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva |
IN192057B (hr) * | 2001-07-19 | 2004-02-14 | Ranbaxy Lab Ltd | |
AU2003223105A1 (en) * | 2003-03-24 | 2004-10-18 | Hetero Drugs Limited | Novel crystalline forms of (s)-citalopram oxalate |
AU2003278409A1 (en) * | 2003-10-28 | 2005-05-19 | Krishnaji Upadhye Bhargav | Improved process for the manufacture of citalopram hydrobromide |
US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
DE05815687T1 (de) | 2004-08-23 | 2007-10-18 | Sun Pharmaceutical Industries Ltd. | Verfahren zur herstellung von citalopram und enantiomeren |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1143702A (hr) | 1965-03-18 | |||
GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
GB8419963D0 (en) | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
GB8814057D0 (en) | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
US5296507A (en) | 1990-09-06 | 1994-03-22 | H.Lundbeck A/S | Treatment of cerbrovascular disorders |
DE19626659A1 (de) | 1996-07-03 | 1998-01-08 | Basf Ag | Verfahren zur Herstellung von Phthaliden |
DE19627697A1 (de) | 1996-07-10 | 1998-01-15 | Basf Ag | Verfahren zur Herstellung von Phthaliden |
DK1015416T3 (da) | 1997-07-08 | 2001-11-05 | Lundbeck & Co As H | Fremgangsmåde til fremstilling af citalopram |
UA62985C2 (en) * | 1997-11-10 | 2004-01-15 | Lunnbeck As H | A method for the preparation of citalopram |
JP3813820B2 (ja) * | 1997-11-11 | 2006-08-23 | ハー・ルンドベック・アクチエゼルスカベット | シタロプラムの製造方法 |
EA002977B1 (ru) | 1998-10-20 | 2002-12-26 | Х.Лундбекк А/С | Способ получения циталопрама |
PT1140886E (pt) | 1998-12-23 | 2003-08-29 | Lundbeck & Co As H | Metodo para a preparacao de 5- cianoftalida |
AR022329A1 (es) | 1999-01-29 | 2002-09-04 | Lundbeck & Co As H | Metodo para la preparacion de 5-cianoftalida |
ES2195554T5 (es) | 1999-04-14 | 2010-02-02 | H. Lundbeck A/S | Metodo para la preparacion de citalopram. |
ITMI991581A1 (it) | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | Metodo per la preparazione di citalopram |
ITMI991579A1 (it) | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | Metodo per la preparazione di citalopram |
ITMI991486A1 (it) | 1999-07-06 | 2001-01-06 | Vis Farmaceutici S P A | Processo per la sintesi di citalopram |
ES2169709A1 (es) | 1999-10-25 | 2002-07-01 | Lundbeck & Co As H | Metodo para la preparacion de citalopram |
AR026063A1 (es) | 1999-11-01 | 2002-12-26 | Lundbeck & Co As H | Metodo para la preparacion de 5-carboxiftalida. |
US6310222B1 (en) | 1999-11-01 | 2001-10-30 | Sumika Fine Chemicals Co., Ltd. | Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate |
AU778751B2 (en) | 1999-12-28 | 2004-12-16 | H. Lundbeck A/S | Method for the preparation of citalopram |
ATE253568T1 (de) | 1999-12-30 | 2003-11-15 | Lundbeck & Co As H | Verfahren zur herstellung von citalopram |
WO2001051477A1 (en) | 2000-01-14 | 2001-07-19 | H. Lundbeck A/S | Method for the preparation of 5-cyanophthalide |
IT1317729B1 (it) | 2000-01-18 | 2003-07-15 | Norpharma S P A | Procedimento per la preparazione della 5-carbossiftalide. |
US6433196B1 (en) | 2000-02-17 | 2002-08-13 | Sumika Fine Chemicals Co., Ltd. | Production method of citalopram, intermediate therefor and production method of the intermediate |
FR2805812A1 (fr) | 2000-02-24 | 2001-09-07 | Lundbeck & Co As H | Procede de preparation du citalopram |
IES20010143A2 (en) | 2000-02-24 | 2001-07-25 | Lundbeck & Co As H | Method for the preparation of citalopram |
NL1017417C1 (nl) | 2000-03-03 | 2001-03-16 | Lundbeck & Co As H | Werkwijze voor de bereiding van Citalopram. |
GB0005477D0 (en) | 2000-03-07 | 2000-04-26 | Resolution Chemicals Limited | Process for the preparation of citalopram |
NL1017500C1 (nl) | 2000-03-13 | 2001-04-26 | Lundbeck & Co As H | Werkwijze voor de bereiding van Citalopram. |
GB2357762B (en) | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
JP2003527385A (ja) | 2000-03-13 | 2003-09-16 | ハー・ルンドベック・アクチエゼルスカベット | 5−置換された1−(4−フルオロフェニル)−1,3−ジヒドロイソベンゾフランの段階的アルキル化法 |
PL360110A1 (en) | 2000-03-13 | 2004-09-06 | H.Lundbeck A/S | Method for the preparation of citalopram |
PL360107A1 (en) | 2000-03-14 | 2004-09-06 | H.Lundbeck A/S | Method for the preparation of citalopram |
CZ20023406A3 (cs) | 2000-03-16 | 2003-01-15 | H. Lundbeck A/S | Způsob výroby 5-kyano-1-(4-fluorfenyl)-1,3-dihydroisobenzofuranu |
AR032455A1 (es) | 2000-05-12 | 2003-11-12 | Lundbeck & Co As H | Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva |
IL148525A0 (en) | 2000-07-06 | 2002-09-12 | Lundbeck & Co As H | Method for the preparation of citalopram |
IL144817A0 (en) | 2000-08-18 | 2002-06-30 | Lundbeck & Co As H | Method for the preparation of citalopram |
CA2360303C (en) | 2000-12-22 | 2003-08-12 | Marco Villa | Process for the preparation of pure citalopram |
EP1181272B1 (en) | 2000-12-28 | 2002-08-28 | H. Lundbeck A/S | Process for the preparation of pure citalopram |
-
2001
- 2001-05-07 AR ARP010102152A patent/AR032455A1/es active IP Right Grant
- 2001-05-10 DK DK01931469T patent/DK1296970T3/da active
- 2001-05-10 ES ES01931469T patent/ES2301541T3/es not_active Expired - Lifetime
- 2001-05-10 EA EA200201211A patent/EA005674B1/ru not_active IP Right Cessation
- 2001-05-10 JP JP2001582313A patent/JP2003532721A/ja not_active Withdrawn
- 2001-05-10 WO PCT/DK2001/000333 patent/WO2001085712A1/en active IP Right Grant
- 2001-05-10 EP EP01931469A patent/EP1296970B1/en not_active Expired - Lifetime
- 2001-05-10 DE DE60133280T patent/DE60133280T2/de not_active Expired - Fee Related
- 2001-05-10 CA CA002408292A patent/CA2408292C/en not_active Expired - Fee Related
- 2001-05-10 PT PT01931469T patent/PT1296970E/pt unknown
- 2001-05-10 CZ CZ20024065A patent/CZ20024065A3/cs unknown
- 2001-05-10 MX MXPA02011125A patent/MXPA02011125A/es active IP Right Grant
- 2001-05-10 NZ NZ522475A patent/NZ522475A/en unknown
- 2001-05-10 CN CNB018125859A patent/CN100422166C/zh not_active Expired - Fee Related
- 2001-05-10 HU HU0301942A patent/HUP0301942A2/hu unknown
- 2001-05-10 PL PL01358144A patent/PL358144A1/xx unknown
- 2001-05-10 AU AU5823901A patent/AU5823901A/xx active Pending
- 2001-05-10 AT AT01931469T patent/ATE389645T1/de not_active IP Right Cessation
- 2001-05-10 SK SK1754-2002A patent/SK287035B6/sk not_active IP Right Cessation
- 2001-05-10 AU AU2001258239A patent/AU2001258239B2/en not_active Ceased
- 2001-05-10 SI SI200130831T patent/SI1296970T1/sl unknown
- 2001-05-10 BR BR0110996-0A patent/BR0110996A/pt not_active Application Discontinuation
- 2001-05-10 IL IL15264501A patent/IL152645A0/xx unknown
- 2001-10-05 UA UA2002118821A patent/UA72039C2/uk unknown
-
2002
- 2002-10-31 IS IS6605A patent/IS2586B/is unknown
- 2002-11-04 IL IL152645A patent/IL152645A/en not_active IP Right Cessation
- 2002-11-05 ZA ZA200208973A patent/ZA200208973B/en unknown
- 2002-11-08 HR HRP20020881 patent/HRP20020881A2/hr not_active Application Discontinuation
- 2002-11-08 US US10/291,174 patent/US6660873B2/en not_active Expired - Fee Related
- 2002-11-12 NO NO20025423A patent/NO327963B1/no not_active IP Right Cessation
- 2002-12-03 BG BG107349A patent/BG65820B1/bg unknown
-
2003
- 2003-11-20 HK HK03108460.1A patent/HK1056171A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3813820B2 (ja) | シタロプラムの製造方法 | |
FI108538B (fi) | Menetelmä sitalopraamin valmistamiseksi | |
JP3447267B2 (ja) | シタロプラムの製造方法 | |
HRP20020756A2 (en) | Crystalline base of citalopram | |
ITMI991580A1 (it) | Metodo per la preparazione di citalopram | |
HRP20020743A2 (en) | Method for the preparation of citalopram | |
UA72340C2 (uk) | Спосіб одержання циталопраму | |
HRP20020881A2 (en) | Method for the preparation of citalopram | |
HRP20020757A2 (en) | Method for the preparation of 5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofurans | |
SK9282002A3 (en) | Method for the preparation of citalopram, pharmaceutical composition comprising same and intermediates | |
AU2001258239A1 (en) | Method for the preparation of citalopram | |
HRP20020633A2 (en) | Method for the preparation of citalopram | |
HRP20020744A2 (en) | Method for the preparation of citalopram | |
HRP20020758A2 (en) | Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans | |
HRP20020741A2 (en) | Method for the preparation of citalopram | |
KR100821912B1 (ko) | 시탈로프람의 제조 방법 | |
ZA200107956B (en) | Method for the preparation of citalopram. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
OBST | Application withdrawn | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20090505 Year of fee payment: 9 |